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 ORIGINAL ARTICLE 
 Higher risk of tuberculosis reactivation when anti-TNF is combined 
with immunosuppressive agents: a systematic review of 
randomized controlled trials 
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of host defence against TB is represented by the antigen-specifi c 
adaptive T cell response that is impaired by anti-TNF therapy. 
Recently, it was hypothesized that the depletion of a granulysin-
expressing subset of eff ector memory CD8    T cells (CD8    
TEMRA cells) induced by infl iximab (IFX) could result in sub-
optimal control of mycobacterial growth, leading to the poten-
tial spreading of TB infection (4). Antibodies against TNF are 
known to cause a reactivation of latent TB in animal models of 
the disease (5), and TB cases have been consistently reported in 
patients with rheumatoid arthritis (RA) and Crohn ’ s disease (CD) 
(6), especially in populations at high prevalence of TB infection 
(7,8). When considering the increasing use of anti-TNF therapies 
in these diseases, the burden of TB reactivation may be clinically 
relevant. TB reactivation tends to occur early following initiation 
of the drug, with extra-pulmonary and disseminated manifesta-
tions occurring relatively more frequently than in immunocom-
petent patients (6). Consequently, TB screening prior to anti-TNF 
treatment is currently recommended (9 – 12). 
 Because of its low incidence, anti-TNF-related TB risk has 
been mainly estimated in large uncontrolled populations, such as 
long-term open-label extension trials, registries, and post-mar-
keting surveillance databases (8,13 – 18). However, these estimates 
were likely inaccurate due to several biases from lack of adequate 
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 Key messages 
 Treatment with tumour necrosis factor antagonists  •
(anti-TNF) has been recognized as a risk factor for 
tuberculosis (TB) reactivation. 
 We found that TB risk was higher when anti-TNF agents  •
were combined with immunosuppressive therapy as 
compared with either controls (OR 54) or anti-TNF 
monotherapy (OR 13.3). 
 Objective. Treatment with tumour necrosis factor antagonists 
(anti-TNF) has been recognized as a risk factor for tuberculosis 
(TB) reactivation. Our aim was to evaluate risk of TB reactiva-
tion in rheumatologic and non-rheumatologic diseases treated 
with the same anti-TNF agents with and without concomitant 
therapies. 
 Methods. We searched for randomized controlled trials (RCTs) 
evaluating infl iximab, adalimumab, and certolizumab in 
both rheumatologic and non-rheumatologic diseases until 
2012. Results were calculated as pooled rates and/or pooled 
odd ratios (OR). 
 Results. Overall, 40 RCTs with a total of 14,683 patients (anti-TNF: 
10,010; placebo: 4673) were included. TB reactivation was 0.26% 
(26/10,010) in the anti-TNF group and 0% (0/4673) in the control 
group, corresponding to an OR of 24.8 (95% CI 2.4 – 133). TB risk 
was higher when anti-TNF agents were combined with metho-
trexate or azathioprine as compared with either controls (24/4241 
versus 0/4673; OR 54; 95% CI 5.3 – 88) or anti-TNF monotherapy 
(24/4241 versus 2/5769; OR 13.3; 95% CI 3.7 – 100). When anti-
TNF was used as monotherapy, TB risk tended to be higher than 
placebo (2/5769 versus 0/4673; OR 4; 95% CI 0.2 – 15.7). 
 Conclusions. TB risk with anti-TNF agents appeared to be increased 
when these agents were used in combination with methotrexate 
or azathioprine as compared with monotherapy regimen. TB risk 
seemed to be higher than placebo, even when monotherapy is 
prescribed. 
 Key words:  Ankylosing spondylitis ,  anti-TNF ,  infl ammatory bowel 
diseases ,  methotrexate ,  psoriasis ,  rheumatoid arthritis ,  tuberculosis 
 Introduction 
 Tumour necrosis factor (TNF) has been shown to play a critical 
role in the host response against tuberculosis (TB), including gran-
uloma integrity and containment of disease (1 – 3). A key aspect 
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control groups and clinical under-reporting. On the other hand, 
estimates from individual randomized controlled trials (RCTs) 
are more likely to be reliable, but are limited by small sample 
size and/or short study duration. To overcome these limitations, 
the anti-TNF-related risk of TB reactivation has been estimated 
in systematic reviews, where pooling data from individual RCTs 
substantially increases the confi dence in the fi nal estimate (19 – 21). 
Although this methodology has been mainly applied to assess the 
treatment-related TB risk in individual diseases (19 – 21), a recent 
meta-analysis estimated the adverse eff ects of diff erent biologic 
drugs — including anti-TNF — in several diseases (i.e. all but HIV 
infection) (22). A 4.7-fold increase of TB reactivation risk during 
anti-TNF therapy as compared to placebo has been shown in an 
overall study population of 163 RCTs (5010 participants) and 46 
extension studies (11,954 participants) (23). 
 However, the role of other factors potentially associated with 
TB reactivation during anti-TNF therapy has not been fully 
ascertained. Th erefore, we performed a systematic review of 
RCTs of only three anti-TNF agents used in both rheumatologic 
and non-rheumatologic diseases — IFX, adalimumab (ADA), 
and certolizumab pegol (CERT) — in order to compare the risk 
of TB between the treatment and placebo groups, and to identify 
potential predictive factors associated with TB reactivation such 
as the type of disease or the concomitant use of immunosup-
pressive drugs. 
 Methods 
 Methods of the analysis and inclusion criteria were based on 
PRISMA recommendations (24). Th e present review is a selective 
update of a previously published systematic review by Singh et  al. 
which included articles published up to January 2010 (22). 
 Eligibility criteria 
 We considered all RCTs in which the selected anti-TNF agents 
were compared with at least one arm of placebo, and the risk 
of TB reactivation was assessed. For this analysis, we decided 
to limit the present review to RCTs including anti-TNF used 
in more than one disease, namely IFX, ADA, and CERT that 
are applied in RA, ankylosing spondylitis (AS), infl ammatory 
bowel diseases (IBD), psoriasis, and psoriatic arthritis (PA). We 
decided to exclude the very few trials in which anti-TNF agents 
were sporadically used in other diseases, such as viral hepati-
tis, sarcoidosis, etc. We also excluded RCTs with    30 patients 
or with a follow-up duration    12 weeks. Th ese criteria were 
applied both when extracting studies already included in the 
previous review (22), and when considering new studies from 
the literature search. If there was any suspicion of cohort overlap 
between studies, only the most recent study was considered for 
inclusion. RCTs with an open-label phase with anti-TNF before 
randomization were also excluded. 
 Information sources 
 A literature search was performed for the period January 2010 
to March 2012. Relevant publications were identifi ed by MED-
LINE and Cochrane databases. We identifi ed eligible studies with 
the MeSH terms  Tuberculosis ,  Rheumatic diseases ,  Infl ammatory 
bowel diseases ,  Psoriasis ,  Infl iximab ,  Adalimumab ,  Certolizumab 
pegol , and  Randomized controlled trial . Only RCTs published in 
English language were considered. We used bibliographies of all 
relevant studies identifi ed to do a recursive search. When the 
selected randomized study provided insuffi  cient information 
regarding the TB risk, authors were contacted. 
 Study selection 
 Titles and abstracts of papers were screened by four reviewers 
(R.L., A.Z., V.B., C.H.). Studies were independently evaluated 
for relevance by the reviewers (using the full text of the study). 
Any disagreements were resolved through discussion. Data were 
extracted from the included studies by one of the four reviewers 
and checked by a second reviewer, and the data were extracted 
into tables. Any disagreements were resolved through discussion 
with a third reviewer. 
 Data collection 
 From each paper, reviewers independently abstracted the fol-
lowing information: country of origin, type of disease, type and 
dose of anti-TNF, number of patients included in the RCT, study 
duration, concomitant therapies systematically included in the 
active arms or in the control arm according to study protocol, 
performance of TB screening prior to therapy, and number of 
TB cases in each arm. In addition, clinical information about TB 
cases was collected when available. 
 Risk of bias in individual studies 
 Information on the methodological quality of each study was 
recorded, and quality assessment was performed using the 
CONSORT checklist (24). However, since our study focused on 
a secondary end-point of these studies (i.e. TB reactivation), we 
simplifi ed the interpretation of the quality of the primary end-
point (i.e. therapeutic response). Th us, studies with random se-
quence generation, adequate concealment of allocation, blinding 
of participants and personnel, blinding of outcome assessment, 
and adequate outcome were considered at low risk of bias. 
Regarding our study end-point (i.e. TB incidence), we evaluated 
whether a systematic reporting of adverse events was provided in 
each individual study. 
 Summary measures 
 Th e primary end-point of this systematic review was to address 
the risk of TB in the anti-TNF arms as compared with those allo-
cated in the control group, and whether there was an association 
of such risk with other variables, such as the type of disease or 
concomitant medications. 
 Planned methods of analysis 
 For each of the two arms (anti-TNF and controls), we aggregated 
the absolute number of cases with TB. Comparison among groups 
was performed by chi-square test. Pooled estimates and 95% con-
fi dence intervals (CI) were calculated. Th e Number Cruncher 
Statistical System soft ware (NCSS, Kaysville, UT, USA) was used 
for the computations. When considering the rare incidence of TB 
in any of the two arms, we preferred not to adopt a more complex 
meta-analytical approach, because of the well-known bias of this 
methodology with rare events (25). 
 Results 
 Study selection 
 A fl ow diagram of this systematic review, with the number of 
papers retrieved, included, and excluded, as well as the reasons 
for exclusion, is shown in Figure 1. In summary, 259 studies 
were identifi ed by the included databases for the selected pe-
riod, including 59 extracted from the previous meta-analysis 
(22). Aft er removing non-pertinent papers, 109 were regarded 
as relevant. Out of these, 69 were excluded for the reasons 
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reported in Figure 1, while 40 trials were selected for inclusion 
in the systematic review (26 – 65). 
 Characteristics of the included studies 
 Main characteristics of the included studies are provided in 
Table I. Th e studies were performed in either USA and Europe 
( n    18), only USA ( n    11), only Europe ( n    6), or non-USA/
European countries ( n    5). RA was the underlying disease in 
14 studies, AS in 5, psoriasis in 9, PA in 4, and IBD in 8 cases 
(7 Crohn ’ s disease; 1 ulcerative colitis). Th e anti-TNF agent used 
was IFX in 20 studies, ADA in 14, and CERT in 6. In 13 studies, 
the anti-TNF agent was used with a concomitant immunosup-
pressive agent according to the study protocol (11 studies with 
methotrexate and 2 with azathioprine), and in 28 studies anti-
TNF agent was used as monotherapy (in one study the active 
group was divided in IFX as monotherapy and IFX   AZA) (32). 
 Participants 
 A total of 14,683 subjects were randomized in the selected studies 
(Table I). Of these, 10,010 were allocated in the active arm, and 
the remaining 4673 in the control arm. In detail, 2941 controls 
received only placebo, while the remaining 1732 were allocated 
to placebo plus methotrexate (MTX) or azathioprine (AZA). Th e 
number of patients enrolled for study ranged from 47 to 1212, 
with a median of 275. Th e median duration of follow-up was 
24 weeks, ranging from 12 to 54 weeks. Th e doses ranged from 
5 to 20 mg/kg for IFX, from 100 to 400 mg for CERT, from 20 to 
80 mg for ADA, from 2 to 2.5 mg/kg for AZA, and from 12.5 to 
25 mg for MTX. TB screening was clearly stated to be performed 
in 27 RCTs, no screening was carried out in 3 series, while this 
information was unavailable in other 10 trials (Table II). In detail, 
TB screening was performed with only chest X-ray in 5 studies, 
only purifi ed protein derivative (PPD) test in 2, and with PPD 
plus chest X-ray in the remaining 20 series. Only a few studies 
provided information on how TB screening-positive cases were 
evaluated. As shown in Table II, positive cases were excluded 
from the RCT in 18 studies, while preventive TB therapy was 
administered in 8 studies. Finally, 4 studies excluded those with a 
clinical history of TB. 
 Quality of the studies 
 All the included trials appeared to be at low risk of bias when 
evaluated by criteria defi ning the quality of the primary 
end-point. All of the included studies systematically reported 
adverse events. 
 TB risk 
 Overall, 26 (0.26%) out of 10,010 patients developed TB in the 
active treatment group, corresponding to an incidence rate of 481 
cases per 100,000 patient-years. No cases of TB were observed 
in the 4673 patients receiving placebo or placebo plus immuno-
suppressive therapy (Table III). Th is diff erence was statistically 
Cochrane Review (until January 2010) = 209 RCTs
Medline from January 2010 to March 2012 = 50 RCTs
(n = 259)
Excluded: 150 RCTs
- Open-label design (n = 44)
- RCTs with other biologics (n = 94)
- RCTs on other diseases (n = 10)
Study retrieved following the first evaluation
(n = 109)
RCTs included
n =  40
Excluded: 69 studies
- Study period <12 weeks (n = 18)
- Number of patients <30 (n = 15)
- RCTs with other biologics (n = 7)
- No safety information (n = 5)
- No placebo group (n = 7)
- Exposition to biologics before placebo (n = 9)
- Post-hoc analysis of previous studies (n = 4)
- Paediatric setting (n = 2)
- Other discordance (n = 2)
- Full paper not retrieved ( N = 1)
 Figure 1. Flow chart of the systematic review. 
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2 disseminated), and information about site of infection was 
missing for the remaining 7 patients. Overall, 10 (40%) TB 
cases were observed in Russia, Estonia, Ukraine, and Bulgaria, 
whilst only 1 case occurred in USA. Screening for TB at entry 
was performed in 21 (84%) of these patients, being negative and 
positive in 11 and 6 cases, respectively (in 4 cases not reported). 
Of note, TB infection occurred in 2 patients who had positive 
screening despite the fact that a preventive anti-TB therapy 
was performed. Nineteen patients recovered with anti-TB 
therapy, and 1 died; outcome information was missing for the 
remaining 5. 
 Discussion 
 According to our systematic review, the combination therapy of 
anti-TNF agents with MTX or AZA results in a 13-fold increase 
in the risk of TB reactivation, as compared with anti-TNF 
agents used in monotherapy. Combination therapy is usually 
performed in rheumatic diseases and, more recently, also in IBD 
patients (30,32,66). Our fi ndings are relevant for several rea-
sons. First, our estimates are based on pooling of 40 RCTs with 
an overall population of over 14,683 patients. Th e high quality 
of the underlying studies is likely to exclude allocation bias be-
tween active and placebo arms, as well as an under-reporting of 
signifi cant (OR 24.8; 95% CI 2.4 – 133;  P   0.01). When stratifying 
for concomitant therapy, patients treated with anti-TNF in mono-
therapy (2/5769 versus 0/4673; OR 4; 95% CI 0.2 – 15.7;  P    0.5), 
as well as those treated with anti-TNF agents combined with 
MTX or AZA (24/4241 versus 0/4673; OR 54; 95% CI 5.3 – 288; 
 P    0.001), appeared to be at higher TB risk, although a statisti-
cally signifi cant diff erence was showed only in the latter group. 
When diff erentiating between the two types of controls, TB risk 
with combination therapy was signifi cantly higher than both 
placebo alone (24/4241 versus 0/2941; OR 34; 95% CI 3.3 – 181; 
P    0.001) and placebo plus immunosuppressive agents (24/4241 
versus 0/1732; OR 20; 95% CI 2 – 107;  P   0.001). TB risk was also 
signifi cantly higher when comparing combined therapy with 
monotherapy (24/4241 versus 2/5769; OR 13.3; 95% CI 3.7 – 100; 
 P   0.001), observing in the former group an incidence rate of 832 
cases per 100,000 patient-years and of 91 in latter group. When 
stratifying for disease, patients treated with anti-TNF agents for 
rheumatologic diseases were not at higher TB risk as compared 
with non-rheumatologic diseases (24/8367 versus 2/1643; OR 1.9; 
95% CI 0.5 – 14; P    0.29). 
 TB cases 
 Data on TB cases are provided in Table IV. Th ere were 9 pul-
monary localizations, 9 extra-pulmonary infections (including 
 Table I. Characteristics of included trials. 
Reference Country Patients Disease Drug Control FU
Targan et  al. (26) USA, Europe 108 CD IFX Placebo 12
Present et  al. (27) USA, Europe 94 CD IFX Placebo 18
Winter et  al. (28) USA, Europe, South Africa 92 CD CERT Placebo 12
Schreiber et  al. (29) USA, Canada, Europe 292 CD CERT Placebo 12
Lemann et  al. (30) France 113 CD IFX   AZA Placebo   AZA 52
Sandborn et  al. (31) USA, Canada, Europe, South Africa 660 CD CERT Placebo 26
Colombel et  al. (32) Europe, USA, Israel 508 CD IFX   AZA/IFX a Placebo   AZA 26
Sandborn et  al. (33) USA, Canada, Europe, 728 UC IFX Placebo 54
Maini et  al. (34) USA, Europe 428 RA IFX   MTX Placebo   MTX 30
Weinblatt et  al. (35) USA 271 RA ADA   MTX Placebo   MTX 24
Furst et  al. (36) USA, Europe 636 RA ADA Placebo 24
van de Putte et  al. (37) Th e Netherlands 544 RA ADA Placebo 26
Keystone et  al. (38) USA, Canada 619 RA ADA   MTX Placebo   MTX 52
St Clair et  al. (39) USA, Canada, Europe 1049 RA IFX   MTX Placebo   MTX 46
Abe et  al. (40) Japan 147 RA IFX   MTX Placebo   MTX 14
Westhovens et  al. (41) USA, Europe, Argentina 1084 RA IFX   MTX Placebo   MTX 22
Schiff  et  al. (42) USA, South America 275 RA IFX   MTX Placebo   MTX 52
Miyasaka (43) Japan 352 RA IFX   MTX Placebo 24
Keystone et  al. (44) USA, Canada, Europe 982 RA CERT   MTX Placebo   MTX 52
Fleischmann et  al. (45) USA, Europe 220 RA CERT Placebo 24
Smolen et  al. (46) USA, Europe 619 RA CERT   MTX Placebo   MTX 24
Chen et  al. (47) Taiwan 47 RA ADA   MTX Placebo   MTX 12
Braun et  al. (48) Germany 69 AS IFX Placebo 12
van der Heijde et  al. (49) USA, Europe 279 AS IFX Placebo 24
van der Heijde et  al. (50) USA, Europe 315 AS ADA Placebo 24
Lambert et  al. (51) USA, Canada 82 AS ADA Placebo 24
Inman et  al. (52) Canada 76 AS IFX Placebo 12
Gottlieb et  al. (53) USA 249 P IFX Placebo 30
Reich et  al. (54) Europe, Canada 378 P IFX Placebo 24
Gordon et  al. (55) USA 147 P ADA Placebo 12
Menter et  al. (56) USA, Canada 835 P IFX Placebo 14
Saurat et  al. (57) Switzerland 161 P ADA Placebo 16
Menter et  al. (58) USA 1212 P ADA Placebo 16
Asahina et  al. (59) Japan 169 P ADA Placebo 24
Torii et  al. (60) USA, Canada 54 P IFX Placebo 16
Leonardi et  al. (61) USA, Canada, Europe 72 P ADA Placebo 16
Antoni et  al. (62) USA, Canada, Europe 104 PA IFX Placebo 16
Antoni et  al. (63) USA, Canada, Europe 200 PA IFX Placebo 24
Mease et  al. (64) USA 313 PA ADA Placebo 24
Genovese et  al. (65) USA, Canada 100 PA ADA Placebo 12
 ADA    adalimumab; AS    ankylosing spondylitis; AZA    azathioprine; CD    Crohn ’ s disease; CERT    certolizumab pegol; FU    follow-up (weeks); 
IFX    infl iximab; MTX    methotrexate; P    psoriasis; PA    psoriatic arthritis; RA    rheumatoid arthritis; UC    ulcerative colitis. 
 a Active group was divided between IFX and IFX   AZA. 
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TB cases between combined and monotherapy. Due to the large 
number of patients pooled, it is unlikely that new individual 
RCTs will aff ect the main result of our analysis. Second, we 
showed for the fi rst time that TB risk is aff ected by concomitant 
medications. Th is is in agreement with the results of a recent 
meta-analysis of RCTs of ADA and IFX — where    70% of pa-
tients were treated with a combination therapy — that showed 
a 2-fold increased risk of serious infections compared with 
placebo (19). Th us, a more intensive screening and surveillance 
approach seems to be advisable when combined therapy is used. 
Of note, our results are also in agreement with a recent analysis 
from the FDA adverse event-reporting system (67), showing a 
4-fold increased risk of mycobacterial infections in those with 
combined therapy versus monotherapy. Th ird, we confi rmed a 
higher risk of TB reactivation also in patients with anti-TNF 
monotherapy. Th e fact that the diff erence as compared with pla-
cebo did not reach statistical signifi cance in our analysis may be 
simply referred to the small number of events, since only two 
 Table II. Screening for tuberculosis (TB) infection and incidence of TB in the included studies. 
Reference Screening for TB
Measure adopted 
when positive
TB cases in 
Th erapy ( n )
TB cases in 
Control ( n )
Targan et  al. (26) No  – 0/83 0/25
Present et  al. (27) No  – 0/63 0/31
Winter et  al. (28) No  – 0/68 0/24
Schreiber et  al. (29) Chest radiograph Excluded 0/219 0/73
Lemann et  al. (30) PPD test Excluded 0/57 0/56
Sandborn et  al. (31) PPD test plus chest radiograph Excluded 0/331 0/329
Colombel et  al. (32) PPD test plus chest radiograph Excluded 1/338 a 0/170
Sandborn et  al. (33) PPD test plus chest radiograph Excluded 1/484 0/244
Maini et  al. (34) NA  – 1/340 0/88
Weinblatt et  al. (35) PPD test Th erapy 0/209 0/62
Furst et  al. (36) PPD test plus chest radiograph Th erapy in some 0/318 0/318
van de Putte et  al. (37) Chest radiograph Excluded 0/434 0/110
Keystone et  al. (38) PPD test plus chest radiograph Th erapy in some 1/419 0/200
St Clair et  al. (39) PPD test plus chest radiograph NA 4/751 0/298
Abe et  al. (40) NA  – 0/100 0/47
Westhovens et  al. (41) PPD test plus chest radiograph Excluded 4/721 0/363
Schiff  et  al. (42) PPD test plus chest radiograph 2/165 0/110
Miyasaka (43) PPD test plus chest radiograph 0/265 0/87
Keystone et  al. (44) PPD test plus chest radiograph Th erapy 5/783 0/199
Fleischmann et  al. (45) PPD test plus chest radiograph 0/111 0/109
Smolen et  al. (46) PPD test plus chest radiograph 5/492 0/127
Chen et  al. (47) NA  – 1/35 0/12
Braun et  al. (48) Chest radiograph Excluded 1/34 0/35
van der Heijde et  al. (49) PPD test plus chest radiograph Th erapy 0/201 0/78
van der Heijde et  al. (50) PPD test plus chest radiograph Excluded 0/208 0/107
Lambert et  al. (51) NA  – 0/38 0/44
Inman et  al. (52) NA Excluded if history 0/39 0/37
Gottlieb et  al. (53) NA Excluded if history 0/198 0/51
Reich et  al. (54) NA Excluded if history 0/301 0/77
Gordon et  al. (55) PPD test plus chest radiograph Excluded 0/95 0/52
Menter et  al. (56) NA  – 0/627 0/208
Saurat et  al. (57) PPD test plus chest radiograph Excluded 0/108 0/53
Menter et  al. (58) PPD test plus chest radiograph Th erapy 0/814 0/398
Asahina et  al. (59) PPD test plus chest radiograph Th erapy 0/123 0/46
Torii et  al. (60) NA Excluded if history 0/35 0/19
Leonardi et  al. (61) NA  – 0/49 0/23
Antoni et  al. (62) PPD test plus chest radiograph Excluded 0/52 0/52
Antoni et  al. (63) PPD test plus chest radiograph Excluded 0/100 0/100
Mease et  al. (64) Chest radiograph Excluded 0/151 0/162
Genovese et  al. (65) Chest radiograph Excluded 0/51 0/49
 NA    not available; PPD    purifi ed protein derivative. 
 a Th is case occurred in the IFX   AZA arm. 
 Table III. TB risk according to diff erent treatments. 
Comparison TB yes/no TB yes/no  P value OR 95% CI
Any active therapy versus controls 26/10,010 0/4,673    0.001 2.4 2.5 – 133
Anti-TNF α   MTX/AZA versus controls 24/4,241 0/4,673    0.001 54 5.3 – 288
Anti-TNF α   MTX/AZA versus placebo   MTX/AZA 24/4,241 0/1,732    0.001 20 2 – 107
Anti-TNF α   MTX/AZA versus placebo 24/4,241 0/2,941    0.001 34 3.3 – 181
Anti-TNF α alone (monotherapy) versus controls 2/5,769 0/4,673 0.5 4 0.2 – 15.7
Anti-TNF α alone (monotherapy) versus placebo   MTX/AZA 2/5,769 0/1,732 0.9 1.5 0.07 – 5.9
Anti-TNF α alone (monotherapy) versus placebo 2/5,769 0/2,941 0.55 2.5 0.1 – 9.9
Anti-TNF α   MTX/AZA versus anti-TNF α alone 
(monotherapy)
24/4,241 2/5,769    0.001 13.3 3.7 – 100
Rheumatologic diseases a versus non-rheumatologic diseases a 24/8,367 2/1,643 0.29 1.9 0.5 – 14
 Anti-TNF α    tumour necrosis factor- α antagonists; AZA    azathioprine; CI    confi dence interval; MTX    methotrexate; 
OR    odds ratio. 
 a Only active treatment arms. 
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etanercept, that are mainly used in rheumatologic conditions. 
Secondly, we did not use a formal meta-analytic approach for 
the well-known limitations when dealing with rare events (25). 
However, the very low frequency of TB events in any study mar-
ginalizes the relevance of inter-study heterogeneity. Th ird, there 
was some heterogeneity in the TB screening and intervention in 
positive cases among studies. However, the sensitivity analysis 
minimized the role of such heterogeneity. Fourth, the median 
duration of the studies included in our systematic review was 
only 24 weeks (range 12 – 54). However, we feel this interval to 
be adequate in order to assess TB risk, since    70% of anti-TNF-
related TB cases have been shown to occur within 90 days from 
the beginning of anti-TNF therapy (6). Of note, the absolute 
estimate of TB risk — ranging between 91 and 832 cases per 
100,000 patient-years — is in agreement with previous incidence 
rates reported in the literature (8,13). Moreover, the overall risk 
of infections seems to be no longer increased aft er the fi rst year 
of follow-up (73). Fift h, glucocorticoid use has been associated 
with an almost 8-fold increased risk of TB reactivation, espe-
cially in those receiving high doses (   15 mg of prednisone) 
for prolonged periods (   1 month), as well as with a 2 – 3-fold 
increase in the risk of hospitalized infections (74,75). Th erefore, 
since the  ‘ on demand ’ use of glucocorticoids was allowed in the 
RCTs analysed in our systematic review, this could have infl u-
enced the TB risk. However, glucocorticoid use appeared to be 
similar between active treatment and control arms, minimizing 
the chances of a selection bias. 
 In conclusion, our systematic review showed a 13-fold increase 
risk of TB reactivation when using anti-TNF therapy in combi-
nation with MTX or AZA as compared with monotherapy. Th is 
warrants the adoption of more intensive screening strategies for 
these patients. Th is should not obviously reduce the awareness 
of TB risk in patients with anti-TNF monotherapy, as already 
supported by the international guidelines. 
TB cases occurred in the monotherapy arm. Of note, in previ-
ous systematic reviews (19 – 22), TB cases were not separated 
between monotherapy and combined therapy, so that it was 
more likely to reach the statistically signifi cant diff erence. Th us, 
we confi rm the importance of TB screening even in patients 
with anti-TNF monotherapy. Our data would indicate that the 
additional TB risk is related with a synergistic eff ect between 
anti-TNF agents and MTX or AZA rather than to an intrinsic 
risk of each immunosuppressive drug. Indeed, the simple ad-
dition of MTX or AZA to placebo did not increase the risk of 
TB as compared with placebo alone. Th is fi nding seems to be 
in contrast with the results of the CORRONA registry in which 
the combination therapy with MTX and TNF antagonists was 
not associated with a synergistic risk of overall and opportu-
nistic infections compared with either agents prescribed alone 
(68). However, this result could be explained by the unexpect-
edly increased risk of opportunistic infections, including TB, 
found in the cohort of patients treated with MTX alone. Such 
a fi nding is not supported by the majority of previous studies 
which failed to show any increase of infection risk with MTX 
(69,70), so that no screening for TB is actually recommended 
in patients treated with MTX as well as AZA (71). Fourth, al-
though TB development tended to be higher in patients with 
rheumatological diseases as compared to those with IBD or 
psoriasis (0.29% versus 0.12%), the diff erence was not statis-
tically signifi cant. Indeed, there is no plausible explanation in 
the pathogenesis and/or natural history of rheumatologic and 
non-rheumatologic diseases to support an intrinsic role of the 
underlying disease in aff ecting the TB risk. Indeed, although 
it has been reported that RA patients are at 2-fold increased 
risk of developing infections when compared with the general 
population (72), no increased TB risk was demonstrated. 
 Th ere are limitations in the present analysis. Our results 
are not immediately generalizable to anti-TNF agents, such as 
 Table IV. Data of patients who developed tuberculosis (TB) in diff erent trials. 
Ref. Disease Th erapy
Screening 
(result) Site of TB
Timing 
(weeks) Country Outcome
(33) UC IFX yes (neg) lung NA NA recovered
(34) RA IFX   MTX no disseminated 30 – 54 NA dead
(38) RA ADA   MTX yes (neg) lymph nodes NA NA recovered
(39) RA IFX   MTX 1 yes (neg)
 1 yes (neg)
 1 no
 1 no
1 lung
 1 lung
 1 lung
 1 lung
6
 6
 14
 46
1 Europe
 1 Europe
 1 Europe
 1 USA
recovered
 recovered
 recovered
 recovered
(41) RA IFX   MTX 1 yes (NA)
 1 yes (NA)
 1 yes (NA)
 1 yes (NA)
1 lung
 1 extra-lung
 1 extra-lung
 1 extra-lung
28
 23
 12
 26
1 Europe
 1 Europe
 1 Europe
 1 Europe
recovered
 recovered
 recovered
 recovered
(42) RA IFX   MTX 1 yes (neg)
 1 yes (neg)
1 lung
 1 peritoneum
26 – 52
 26 – 52
1 NA
 1 NA
recovered
 recovered
(44) RA CERT   MTX 1 yes (neg)
 1 yes (neg)
 1 yes (pos) a 
 1 yes (pos) a 
 1 yes (pos) a 
NA
 NA
 NA
 NA
 NA
6 – 36
 6 – 36
 6 – 36
 6 – 36
 6 – 36
1 Russia
 1 Russia
 1 Estonia
 1 Ukraine
 1 Bulgaria
NA
 NA
 NA
 NA
 NA
(46) RA CERT   MTX 1 yes (pos) b 
 1 yes (pos) b 
 1 yes (pos) a 
 1 yes (neg)
 1 yes (neg)
1 disseminated
 1 lung
 1 peritoneum
 1 NA
 1 NA
7 – 24
 7 – 24
 7 – 24
 7 – 24
 7 – 24
1 Russia
 1 Russia
 1 Russia
 1 Poland
 1 Latvia
recovered
 recovered
 recovered
 recovered
 recovered
(47) RA ADA   MTX yes (neg) lung 6 Taiwan recovered
(48) AS IFX no lymph nodes/spleen 6 NA recovered
 ADA    adalimumab; AS    ankylosing spondylitis; CERT    certolizumab pegol; IFX    infl iximab; MTX    methotrexate; 
NA    not available; RA    rheumatoid arthritis; UC    ulcerative colitis. 
 a No preventive therapy for TB. 
 b Preventive TB therapy performed. 
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